A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

NCT05265975 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped The adjustment of the sponsor's research and development strategy

Conditions

Diffuse Large B-cell Lymphoma
Indolent Non-Hodgkin Lymphoma

Interventions

DRUG: ATG-010
DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

Antengene Corporation